Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramelteon - Takeda

Drug Profile

Ramelteon - Takeda

Alternative Names: Ramelteon SL; Ramelteon sublingual; Rozerem; TAK-375; TAK-375SL

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Sun Pharmaceutical Industries; Takeda
  • Class Anxiolytics; Indenes; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Discontinued Alzheimer's disease; Bipolar depression; Bipolar disorders; Circadian rhythm sleep disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insomnia(In adolescents, In children) in USA (PO, Tablet)
  • 11 Sep 2015 Discontinued - Phase-III for Bipolar depression (Adjunctive treatment) in USA, United Kingdom, Poland, Bulgaria, Czech Republic, Germany, Romania, Russia, Serbia, Ukraine, Argentina, Canada, Chile, Colombia, Mexico (Sublingual) before 15 May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top